• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding Ltd (OP: RHHVF )

    322.66 +1.59 (+0.50%)
    Streaming Delayed Price Updated: 9:58 AM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,020
    Open 322.23
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 321.07
    Today's Range 322.23 - 323.95
    52wk Range 233.12 - 332.73
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
    Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
    Via MarketBeat
    Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
    Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    +13.00%
    +13.00%
    1 Month
    +11.73%
    +11.73%
    3 Month
    +23.50%
    +23.50%
    6 Month
    +24.54%
    +24.54%
    1 Year
    +8.73%
    +8.73%

    More News

    Read More
    Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
    Via Benzinga
    Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
    Via Benzinga
    Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
    Via Benzinga
    Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
    Via Benzinga
    Exposures Product Safety
    Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
    Via Benzinga
    Exposures COVID-19
    What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
    Via Benzinga
    Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
    Via Benzinga
    Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
    Via Benzinga
    Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
    Via Benzinga
    Exposures COVID-19
    Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
    Via Benzinga
    Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
    Via Benzinga
    Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
    Via Benzinga
    Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
    Via Benzinga
    Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
    Via Benzinga
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Via Benzinga
    Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    Via Benzinga
    Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
    Via Benzinga
    Nvidia Invested $50 million into This AI Drug Discovery Biotech
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
    Via Benzinga
    Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
    Via Benzinga
    Agilent Technologies Stock: Ready to Rise off the Floor
    Via MarketBeat
    DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.